Clinical Trials Logo

Convalescent Plasma clinical trials

View clinical trials related to Convalescent Plasma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05077930 Completed - COVID-19 Clinical Trials

Convalescent Plasma Therapy for Hospitalized Patients With COVID-19

Start date: January 6, 2022
Phase: Phase 2
Study type: Interventional

Plasma from donors who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies to SARS-CoV-2 and may be a potential therapy for hospitalized patients with COVID-19. The efficacy of high-titer convalescent plasma for COVID-19, however, still unclear. The present study aims to evaluate the efficacy and safety of using convalescent plasma for treating hospitalized patients with COVID-19.

NCT ID: NCT04884477 Completed - COVID-19 Clinical Trials

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

Start date: June 1, 2021
Phase:
Study type: Observational

This study is being conducted to determine if patients with compromised B-cell function due to anti-CD20 therapy and newly diagnosed COVID-19 infection benefit from convalescent plasma.

NCT ID: NCT04816942 Completed - Covid19 Clinical Trials

Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt

Start date: April 23, 2020
Phase: Phase 3
Study type: Interventional

One investigational treatment being explored for COVID-19 is the use of convalescent plasma collected from individuals who have recovered from COVID-19 (Refs. 1-4). Convalescent plasma that contains antibodies to severe acute respiratory syndrome coronavirus 2 or SARSCoV-2 (the virus that causes COVID-19) is being studied for administration to patients with COVID-19. Use of convalescent plasma has been studied in outbreaks of other respiratory infections, including the 2003 SARS-CoV-1 epidemic, the 2009-2010 H1N1 influenza virus pandemic, and the 2012 MERS-CoV epidemic (Refs. 5-7). Although promising, convalescent plasma has not yet been shown to be safe and effective as a treatment for COVID-19. Therefore, it is important to study the safety and efficacy of COVID19 convalescent plasma in clinical trials. This guidance provides recommendations to health care providers and investigators on the administration and study of investigational convalescent plasma collected from individuals who have recovered from COVID-19 (COVID-19 convalescent plasma) during the public health emergency. This guidance also provides recommendations to blood establishments on the collection of COVID-19 convalescent plasma..

NCT ID: NCT04397523 Completed - COVID-19 Clinical Trials

Efficacy and Safety of COVID-19 Convalescent Plasma

Start date: April 30, 2020
Phase: N/A
Study type: Interventional

Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection

NCT ID: NCT04392232 Completed - COVID-19 Clinical Trials

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

Start date: May 5, 2020
Phase: Phase 2
Study type: Interventional

Purpose of Study • The purpose of this study to evaluate, the effectiveness of convalescent plasma in combatting the symptoms and effects of the coronavirus disease, COVID-19. Beyond supportive care, there are no proven treatment options for COVID-19.